Daiichi Sankyo and GENESIS Pharma have an exclusive license and supply agreement for distribution and commercialization of quizartinib, brand name VANFLYTA. Thirteen markets in Central and Eastern Europe will be impacted.

Quizartinib is indicated for treatment of adults with FMS-like tyrosine kinase 3—internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML). As branded, VANFLYTA is available in oral form. More than 30 countries and regions have advanced the treatment.

Daiichi, GENESIS Leaders React

“This new strategic collaboration marks another significant milestone for our company, reinforcing our long-standing expertise and focus on advancing medicines for difficult-to-treat cancers,” said Constantinos Evripides, Managing Director, GENESIS Pharma.

“We aim to accelerate access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML and ultimately help improve outcomes in this high-risk population,” said Markus Kosch, MD, Head, Oncology Business Division Europe and Canada, Daiichi Sankyo.

VANFLYTA’s Commercialization

Under the agreement, Daiichi Sankyo will manufacture and supply VANFLYTA. GENESIS Pharma will lead medical affairs, market access, and commercialization. Markets include Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.

In November 2023, the European Union approved VANFLYTA in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy. Another indication for VANFLYTA is as maintenance monotherapy following consolidation.

In Europe, AML impacts approximately 18,000 patients per year. According to reports, the five-year survival rate is 17% for adult patients. In those patients, FLT3-ITD mutations occur in about 25% to 30% of cases.

Daiichi Sankyo’s Latest

Earlier in January 2026, Daiichi Sankyo announced plans to invest approximately $1.9 billion to build manufacturing facilities for cancer drugs. The United States, Japan, Germany, and China are destinations for those facilities.

As reported by Nikkei, Daiichi Sankyo intends to expand its production capabilities for the antibody-drug conjugate ENHERTU and other drugs.